Erratum: Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis

Production Office, Frontiers

doi:10.3389/fgene.2023.1169919

ERRATUM article

Front. Genet. , 03 March 2023

Sec. Human and Medical Genomics

Volume 14 - 2023 | https://doi.org/10.3389/fgene.2023.1169919

Erratum: Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis

This article is an erratum on:

Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis
1. Read original article

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis

by Lorena L, Maristella P, Federica M, Giuseppe F, Luigi A and Eleonora C (2023). Front. Genet. 14:1076421. doi: 10.3389/fgene.2023.1076421

Due to a production error, each author’s first name and surname were erroneously interchanged. The corrected author list appears below.

“Lorena Lorefice, Maristella Pitzalis, Federica Murgia, Giuseppe Fenu, Luigi Atzori, Eleonora Cocco“

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: multiple sclerosis, genomics, transcriptomics, proteomics, metabolomics, disease-modifying treatments, efficacy, safety

Citation: Frontiers Production Office (2023) Erratum: Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis. Front. Genet. 14:1169919. doi: 10.3389/fgene.2023.1169919

Received: 20 February 2023; Accepted: 20 February 2023;
Published: 03 March 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Erratum: Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis

Publisher’s note

94% of researchers rate our articles as excellent or good

94% of researchers rate our articles as excellent or good